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One of the principal aims of the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) is the collection and analysis of
information on addiction and its consequences
for both drug users and the wider population.
Intravenous drug users (IDUs) constitute by far
the largest reservoir of hepatitis C virus (HCV)
infection in Europe, and injecting drug use
remains the major risk-factor for the acquisition
of the virus. HCV is now recognised as a major
healthcare problem in the European Union, and
policies for reducing the burden of infection must
be based on understanding the epidemiology,
natural history and dynamics of HCV transmis-
sion in IDUs. However, evidence-based informa-
tion in this population is particularly difficult to
acquire. Furthermore, there is an urgent need to
develop tools to guide cost-effective intervention.
This monograph aims to integrate current know-
ledge and research findings, and has the stated
intention of providing an up-to-date basis for
policy-making in this important area.
The monograph is divided into five sections:
part I provides general information on the epi-
demiology, natural history, treatment and pre-
vention of HCV; part II deals with models of HCV
transmission, injecting drug use and policy
options; part III addresses the healthcare costs of
drug-related HCV infection; part IV places these
issues in the wider context of the costs of drug
use; and part V assesses the efficacy of nee-
dle and syringe programmes and methadone
maintenance. Each part of the book is structured
logically and contains a useful introduction that
places subsequent chapters in the appropriate
context.
The standards of presentation are high.
Although details of, for example, mathematical
and pharmaco-economic modelling may evade
some readers, every effort has been made to
render these sections accessible, and the limita-
tions of each model are analysed clearly and
critically. Contributors have been allowed to
express individual perspectives, but these views
have been well-marshalled by the editors, and
each section and chapter is cross-referenced.
Overall, this monograph is a valuable attempt to
describe and quantify the HCV epidemic in the
European Union, and to apply the best available
research methods to evaluate potential interven-
tions. While it is always easy to criticise individual
statements—for example, the assertion that only
Luxembourg,Greece and (possibly)Germany offer
treatment to IDUs is not consonant with the policy
of my own and many other UK units—the only
actual weaknesses of this book arise from the very
issues it sets out to address. There aremajor gaps in
our knowledge of all aspects of HCV infection in
IDUs, and corresponding major deficiencies in the
information required to develop accurate models
of the behaviour of HCV or to assess the likely
efficacy of intervention. Furthermore, tools for the
effective study of other diseases, such as that
caused by human immunodeficiency virus, have
not yet been fully validated in the context of HCV.
Such concerns only serve to underline the import-
ance of this monograph. I consider it to be a very
useful contribution to an increasingly important
public health debate and excellent value for those
with an interest in this vital dimension of the HCV
epidemic.
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